Show simple item record

dc.contributor.authorWilding, CP
dc.contributor.authorLoong, HH
dc.contributor.authorHuang, PH
dc.contributor.authorJones, RL
dc.date.accessioned2020-07-06T10:55:20Z
dc.date.issued2020-07
dc.identifier.citationCurrent opinion in oncology, 2020, 32 (4), pp. 307 - 313
dc.identifier.issn1040-8746
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3803
dc.identifier.eissn1531-703X
dc.identifier.doi10.1097/cco.0000000000000650
dc.description.abstractPurpose of review Genetic aberrations resulting in tropomyosin receptor kinase (TRK) fusion proteins can drive oncogenesis and are postulated to occur in up to 1% of solid tumours. However, TRK fusions in adult sarcomas are rare and there is a significant challenge in identifying patients with sarcomas harbouring TRK fusions in the clinical setting. Despite a recent European Society of Medical Oncology consensus article regarding screening of tumours for TRK fusions, economical and practical limitations present a barrier to widespread screening of sarcomas.Recent findings Larotrectinib and entrectinib are pan-TRK inhibitors which have both received FDA approval for the management of solid tumours harbouring NTRK fusions. Initial results of a number of clinical trials have demonstrated promising efficacy and safety data, including dramatic and durable responses in patients with sarcomas. As such, TRK inhibitors represent a promising treatment option in a small cohort of adult sarcoma patients, where currently treatment options are limited. The emergence of acquired resistance is a concern associated with TRK inhibitor therapy and a number of second-generation agents targeting TRK kinase mutations driving acquired resistance have entered early-phase clinical trials.Summary With the growing appreciation of the implications of TRK fusions, this review will summarize the emerging clinical trial data of TRK inhibitors in sarcomas. Although in their infancy, clinical trial results are encouraging, and as further results and analyses are released, we will have a greater understanding of their impact on clinical practice and the management of patients with sarcomas.
dc.formatPrint
dc.format.extent307 - 313
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectHumans
dc.subjectSarcoma
dc.subjectBenzamides
dc.subjectPyrazoles
dc.subjectIndazoles
dc.subjectPyrimidines
dc.subjectReceptor, trkA
dc.subjectReceptor, trkC
dc.subjectOncogene Proteins, Fusion
dc.subjectProtein Kinase Inhibitors
dc.subjectClinical Trials, Phase I as Topic
dc.subjectClinical Trials, Phase II as Topic
dc.titleTropomyosin receptor kinase inhibitors in the management of sarcomas.
dc.typeJournal Article
rioxxterms.versionofrecord10.1097/cco.0000000000000650
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2020-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCurrent opinion in oncology
pubs.issue4
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/18/19 Starting Cohort
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/18/19 Starting Cohort
pubs.publication-statusPublished
pubs.volume32
pubs.embargo.termsNot known
icr.researchteamMolecular and Systems Oncologyen_US
dc.contributor.icrauthorWilding, Christopheren
dc.contributor.icrauthorHuang, Paulen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record